Name: 글로벌 시장 동향
SKU: PH4712
Availability: InStock

보고서 요약(국문)

시장 개요
전 세계 기저 인슐린(장기 지속형 인슐린) 시장은 2022년 2억 3,480만 달러 규모에 도달했으며, 2030년까지 3억 3,160만 달러에 이를 것으로 예상되어 높은 성장세를 보일 전망입니다. 전 세계 기저 인슐린(장기 지속형 인슐린) 시장은 예측 기간(2023~2030년) 동안 연평균 4.5%의 성장률을 기록할 것으로 예상됩니다.
당뇨병 발병률 증가, 유리한 치료비 상환 지침, 신제품 출시, 제품 승인, 기업 합병, 투자, 파트너십, 사업 확장 등 시장 개발 요인들이 전 세계 기저 인슐린(장기 지속형 인슐린) 시장 성장을 견인하고 있습니다. 이 시장의 주요 업체로는 Novo Nordisk AS, Sanofi Aventis, Biocon 등이 있습니다.
시장 동향
당뇨병 발병률 증가가 기저 인슐린(장기 지속형 인슐린) 시장 성장을 주도하고 있습니다.

당뇨병 환자 수의 증가가 전 세계 기저 인슐린(지속형 인슐린) 시장 성장을 견인하고 있습니다. 예를 들어, 의약품 접근성 재단(Access to Medicine Foundation)에 따르면 전 세계적으로 당뇨병 환자가 급증하고 있으며, 매년 670만 명이 사망하고 있습니다. 인슐린 접근성은 점점 더 중요한 국제적 보건 문제로 대두되고 있습니다. 전 세계 당뇨병 환자 수는 2030년까지 6억 4,300만 명, 2045년까지 7억 8,300만 명을 넘어설 것으로 예상되며, 특히 저소득 및 중소득 국가(LMICs)에서 가장 빠르게 증가하고 있습니다. 이러한 국가에서는 인슐린 접근성에 심각한 불평등이 존재합니다.
다양한 환자 지원 프로그램의 존재는 시장 성장을 위한 유망한 기회를 창출합니다.
다양한 환자 지원 프로그램은 향후 몇 년 동안 시장에 유망한 성장 기회를 제공합니다. 예를 들어, 릴리 케어 프로그램(Lilly Cares Program), 노보 노디스크 환자 지원 프로그램(Novo Nordisk Patient Assistance Program, PAP) 노보케어(NovoCare), 인슐린 ValYOU 절약 프로그램(Insulins ValYOU Savings Program), 직접 구매 프로그램(Direct Purchase Program), 인슐린 글라진 후속 생물학적 제제(Insulin Glargine Follow-On Biologic) 등은 인슐린 구매 시 저렴한 가격 또는 상환 지원을 제공합니다. 엄격한 규제 당국이 시장 성장을 저해합니다.
인슐린 제품의 개발 및 상용화를 규제하는 엄격한 규제 당국의 존재는 전 세계 기저 인슐린(장시간 작용 인슐린) 시장 성장을 둔화시키고 있습니다. 예를 들어, 인슐린 개발 및 상용화를 규제하는 주요 기관으로는 FDA와 EMA가 있습니다. 위에서 언급한 요인들이 기저 인슐린(장시간 작용 인슐린) 시장 성장을 제한하고 있습니다.
COVID-19 영향 분석
COVID-19 팬데믹과 전 세계 여러 국가의 봉쇄 조치로 인해 모든 산업 분야 기업의 재정 건전성이 영향을 받았습니다. 따라서 COVID-19 공중 보건 비상 사태 기간 동안 미국 식품의약국(FDA)은 임상시험 참여자의 안전을 보장하고, 우수 임상 실무(GCP)를 준수하며, 임상시험의 무결성에 대한 위험을 최소화하는 등 스폰서와 연구자를 지원하기 위한 일반적인 고려 사항을 포함하는 지침을 발표했습니다.

러시아-우크라이나 전쟁 영향 분석
러시아-우크라이나 분쟁은 해당 지역의 주요 시장 참여 업체가 적고 시장 점유율이 낮기 때문에 전 세계 기저 인슐린(장시간 작용 인슐린) 시장에 중간 정도의 영향을 미칠 것으로 예상됩니다. 그러나 러시아군의 지속적인 침공에 직면한 우크라이나 병원들은 사망자 수 증가와 제한된 의료 물자로 어려움을 겪고 있습니다. 모든 종류의 의약품 부족 현상이 나타나고 있지만, 특히 인슐린 부족으로 인해 당뇨병 관리가 제대로 되지 않아 관련 질환이 증가하고 있습니다. 또한, 원자재 수출입은 예측 기간 동안 전 세계 기저 인슐린(장시간 작용 인슐린) 시장 성장에 큰 영향을 미치지 않을 것으로 예상됩니다.
시장 세분화 분석
전 세계 기저 인슐린(장시간 작용 인슐린) 시장은 제품 유형, 적용 분야, 유통 채널 및 지역별로 세분화됩니다.
병원 약국 부문이 시장 점유율의 40%를 차지합니다.

병원 수 증가, 연구 개발의 활성화, 그리고 간편한 보험금 지급 덕분에 병원 약국 부문은 전 세계 시장 점유율의 42.3%를 차지할 것으로 예상됩니다. 예를 들어, 에스토니아 의약품청에 따르면 2022년 병원 약국의 총 수익은 1억 3,700만 유로로 전년 대비 3% 증가했습니다.
지역별 분석
유럽, 당뇨병 유병률 증가로 시장 점유율 28.6% 차지 예상
유럽의 당뇨병 유병률 증가로 인해 유럽은 전 세계 기저 인슐린(장시간 작용 인슐린) 시장에서 28.6%를 차지하며 두 번째로 큰 시장 점유율을 기록할 것으로 예상됩니다. 예를 들어, 세계보건기구(WHO)에 따르면 유럽 지역에는 약 6천만 명의 당뇨병 환자가 있으며, 이는 25세 이상 남성의 약 10.3%, 여성의 약 9.6%에 해당합니다. 유럽 지역에서 당뇨병 발병률은 모든 연령대에서 증가하고 있는데, 이는 주로 과체중 및 비만 증가, 잘못된 식습관, 그리고 운동 부족 때문입니다.
경쟁 환경
기저 인슐린(장시간 작용 인슐린) 시장의 주요 글로벌 업체로는 Novo Nordisk AS, Sanofi Aventis, Biocon, Julphar, Pfizer, Ganli Pharmaceutical Co., Ltd, Mylan, Wockhardt, Eli Lily 등이 있습니다.
보고서 구매 이유

• 제품 유형, 적용 분야, 유통 채널 및 지역별 글로벌 기저 인슐린(장시간 작용 인슐린) 시장 세분화를 시각화하고 주요 기업 및 주요 업체를 파악하기 위해

• 트렌드 분석 및 공동 개발을 통해 사업 기회를 식별하기 위해 • 모든 세그먼트를 포함한 기저 인슐린(장시간 작용 인슐린) 시장 수준의 다양한 데이터가 담긴 엑셀 데이터 시트.

• 심층적인 질적 인터뷰와 연구를 바탕으로 한 종합적인 분석이 담긴 PDF 보고서.

• 주요 업체들의 핵심 제품을 모두 포함하는 제품 맵핑 엑셀 파일 제공.
글로벌 기저 인슐린(장시간 작용 인슐린) 시장 보고서는 약 53개의 표, 54개의 그림, 195페이지 분량으로 구성됩니다.
주요 고객 (2023년 기준)
• 제조업체/구매자
• 산업 투자자/투자 은행가
• 시장 조사 전문가
• 신흥 기업

보고서 요약(영어 원문)

Market Overview
The Global Basal Insulin (Long-Acting Insulin) Market reached US$ 234.8 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 331.6 million by 2030. The global basal insulin (long-acting insulin) market is expected to exhibit a CAGR of 4.5% during the forecast period (2023-2030).
The rising incidence of diabetes, promising repayment guidelines, and market developments like product introduction, product authorizations, consolidations, investments, partnerships, and expansion among others are boosting the global basal insulin (long-acting insulin) market growth. The key players in this market include Novo Nordisk AS, Sanofi Aventis, and Biocon among others.
Market Dynamics
An Increase In Diabetes Cases Drives The Growth Of The Basal Insulin (Long-Acting Insulin) Market.
The growing cases of diabetes are driving the global basal insulin (long-acting insulin) market growth. For instance, according to the Access to Medicine Foundation, diabetes increases rapidly globally, inducing 6.7 million deaths annually. Access to insulin is an increasingly critical multinational health importance. The number of individuals with diabetes globally is anticipated to surpass 643 million by 2030, and 783 million by 2045 rising most quickly in low- and middle-income countries (LMICs), where there is stark inequity in access to insulin.
Presence Of Various Patient Assistance Programs Creates Lucrative Opportunities For Market Growth.
The presence of various patient assistance programs presents the market with prospective growth opportunities in the upcoming years. For instance, Lilly Cares Program, Novo Nordisk Patient Assistance Program (PAP) NovoCare, Insulins ValYOU Savings Program, Direct Purchase Program, and Insulin Glargine Follow-On Biologic among others provide low-cost or repayment on insulin purchases.
Stringent Regulatory Authorities Hamper the Growth of the Market.
The presence of stringent regulatory authorities controlling the development and commercialization of insulin products slows the global basal insulin (long-acting insulin) market growth. For instance, the major regulatory authorities controlling the development and commercialization of insulin include the FDA and EMA. Above mentioned factors are limiting the basal insulin (long-acting insulin) market growth.
COVID-19 Impact Analysis
The financial health of companies across all industries has been impacted by the COVID-19 pandemic and lockdown in numerous nations throughout the world. Therefore, for the period of the COVID-19 public health emergency, the U.S. Food and Drug Administration (FDA) issued guidelines that include general considerations to aid sponsors and researchers, ensuring the safety of trial participants, adhering to good clinical practice (GCP), and minimizing risks to trial integrity.
Russia-Ukraine War Impact Analysis
The Russia-Ukraine conflict is estimated to have a moderate impact on the global basal insulin (long-acting insulin) market, owing to the low prevalence and absence of key market players in this region. However, persisting to countenance invasions from Russian armies, Ukrainian clinics are pushed by rising numbers of deaths and limited medical reserves. There are deficiencies across all kinds of medicine, but restricted access to insulin reserves has guided to an uptick in disorders associated with uncontrolled diabetes. Also, the influence of the import and export of raw materials are anticipated to have little influence over the global basal insulin (long-acting insulin) market growth over the forecast period.
Segment Analysis
The global basal insulin (long-acting insulin) market is segmented based on product type, application, distribution channels and region.
Hospital Pharmacies Segment Accounts for 40% of the Market Share.
Owing to the increasing number of hospitals, the availability of investigational developments, and ease of reimbursement, the hospital pharmacies segment is estimated to hold 42.3% of the global market share. For instance, according to the Republic of Estonia Agency of Medicines, in 2022, the total earning of hospital pharmacies was 137 million euros, with an upsurge of 3% in total compared to previous results.
Geographical Analysis
Europe is Estimated to Hold 28.6% of the Market Share Owing to the Growing Diabetes Prevalence in this Region
Owing to the growing prevalence of diabetes in Europe, the region is estimated to hold the second-largest share accounting for 28.6% of the global basal insulin (long-acting insulin) market. For instance, according to the World Health Organization, there are approximately 60 million individuals with diabetes in the European Region, or roughly 10.3% of males and 9.6% of females aged 25 years and above. The preponderance of diabetes is rising among all ages in the European Region, principally because of additions in overweight and obesity, harmful diet, and physical laziness.
Competitive Landscape
The major global players in the basal insulin (long-acting insulin) market include Novo Nordisk AS, Sanofi Aventis, Biocon, Julphar, Pfizer, Ganli Pharmaceutical Co., Ltd, Mylan, Wockhardt, and Eli Lily among others.
Why Purchase the Report?
• To visualize the global basal insulin (long-acting insulin) market segmentation based on product type, application, distribution channels and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of basal insulin (long-acting insulin) market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.
The global basal insulin (long-acting insulin) market report would provide approximately 53 tables, 54 figures and 195 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Product Type
3.2. Snippet by Application
3.3. Snippet by Distribution Channels
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Market Developments
4.1.1.2. Growing Prevalence
4.1.2. Restraints
4.1.2.1. Side Effect
4.1.3. Opportunity
4.1.3.1. Reimbursement
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter’s 5 Forces Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID-19
6.1.2. Scenario During COVID-19
6.1.3. Scenario Post COVID-19
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Product Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
7.1.2. Market Attractiveness Index, By Product Type
7.2. Lantus *
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Levemir
7.4. Toujeo
7.5. Tresiba
7.6. Basaglar
7.7. Insulin Glargine Biosimilars
8. By Application
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
8.1.2. Market Attractiveness Index, By Application
8.2. Type 1 Diabetes *
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Type 2 Diabetes
9. By Distribution Channels
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
9.1.2. Market Attractiveness Index, By Distribution Channels
9.2. Hospital Pharmacies *
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Retail Pharmacies
9.4. Online Pharmacies
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.6.1. The U.S.
10.2.6.2. Canada
10.2.6.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.6.1. Germany
10.3.6.2. The U.K.
10.3.6.3. France
10.3.6.4. Spain
10.3.6.5. Italy
10.3.6.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.6.1. Brazil
10.4.6.2. Argentina
10.4.6.3. Rest of South America
10.5. Asia-Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.6.1. China
10.5.6.2. India
10.5.6.3. Japan
Australia
10.5.6.4. Rest of Asia-Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
11. Competitive Landscape
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. Company Profiles
12.1. Novo Nordisk AS*
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Financial Overview
12.1.4. Key Developments
12.2. Sanofi Aventis
12.3. Biocon
12.4. Julphar
12.5. Pfizer
12.6. Ganli Pharmaceutical Co., Ltd
12.7. Mylan
12.8. Wockhardt
12.9. Eli Lily
LIST NOT EXHAUSTIVE
13. Appendix
13.1. About Us and Services
13.2. Contact Us

언급된 주요 기업들

Novo Nordisk AS, 4.	Key Developments, Sanofi Aventis, Biocon, Julphar, Pfizer, Ganli Pharmaceutical Co., Ltd, Mylan, Wockhardt, Eli Lily

표 목록 (Tables)

List of Tables

Table 1 Global Basal Insulin (Long-Acting Insulin) Market Value, By Product Type, 2022, 2026 & 2030 (US$ Million)

Table 2 Global Basal Insulin (Long-Acting Insulin) Market Value, By Application, 2022, 2026 & 2030 (US$ Million)

Table 3 Global Basal Insulin (Long-Acting Insulin) Market Value, By Distribution Channels, 2022, 2026 & 2030 (US$ Million)

Table 4 Global Basal Insulin (Long-Acting Insulin) Market Value, By Region, 2022, 2026 & 2030 (US$ Million)

Table 5 Global Basal Insulin (Long-Acting Insulin) Market Value, By Product Type, 2022, 2026 & 2030 (US$ Million)

Table 6 Global Basal Insulin (Long-Acting Insulin) Market Value, By Product Type, 2021-2030 (US$ Million)

Table 7 Global Basal Insulin (Long-Acting Insulin) Market Value, By Application, 2022, 2026 & 2030 (US$ Million)

Table 8 Global Basal Insulin (Long-Acting Insulin) Market Value, By Application, 2021-2030 (US$ Million)

Table 9 Global Basal Insulin (Long-Acting Insulin) Market Value, By Distribution Channels, 2022, 2026 & 2030 (US$ Million)

Table 10 Global Basal Insulin (Long-Acting Insulin) Market Value, By Distribution Channels, 2021-2030 (US$ Million)

Table 11 Global Basal Insulin (Long-Acting Insulin) Market Value, By Region, 2022, 2026 & 2030 (US$ Million)

Table 12 Global Basal Insulin (Long-Acting Insulin) Market Value, By Region, 2021-2030 (US$ Million)

Table 13 North America Basal Insulin (Long-Acting Insulin) Market Value, By Product Type, 2021-2030 (US$ Million)

Table 14 North America Basal Insulin (Long-Acting Insulin) Market Value, By Application, 2021-2030 (US$ Million)

Table 15 North America Basal Insulin (Long-Acting Insulin) Market Value, By Distribution Channels, 2021-2030 (US$ Million)

Table 16 North America Basal Insulin (Long-Acting Insulin) Market Value, By Country, 2021-2030 (US$ Million)

Table 17 South America Basal Insulin (Long-Acting Insulin) Market Value, By Product Type, 2021-2030 (US$ Million)

Table 18 South America Basal Insulin (Long-Acting Insulin) Market Value, By Application, 2021-2030 (US$ Million)

Table 19 South America Basal Insulin (Long-Acting Insulin) Market Value, By Distribution Channels, 2021-2030 (US$ Million)

Table 20 South America Basal Insulin (Long-Acting Insulin) Market Value, By Country, 2021-2030 (US$ Million)

Table 21 Europe Basal Insulin (Long-Acting Insulin) Market Value, By Product Type, 2021-2030 (US$ Million)

Table 22 Europe Basal Insulin (Long-Acting Insulin) Market Value, By Application, 2021-2030 (US$ Million)

Table 23 Europe Basal Insulin (Long-Acting Insulin) Market Value, By Distribution Channels, 2021-2030 (US$ Million)

Table 24 Europe Basal Insulin (Long-Acting Insulin) Market Value, By Country, 2021-2030 (US$ Million)

Table 25 Asia-Pacific Basal Insulin (Long-Acting Insulin) Market Value, By Product Type, 2021-2030 (US$ Million)

Table 26 Asia-Pacific Basal Insulin (Long-Acting Insulin) Market Value, By Application, 2021-2030 (US$ Million)

Table 27 Asia-Pacific Basal Insulin (Long-Acting Insulin) Market Value, By Distribution Channels, 2021-2030 (US$ Million)

Table 28 Asia-Pacific Basal Insulin (Long-Acting Insulin) Market Value, By Country, 2021-2030 (US$ Million)

Table 29 Middle East & Africa Basal Insulin (Long-Acting Insulin) Market Value, By Product Type, 2021-2030 (US$ Million)

Table 30 Middle East & Africa Basal Insulin (Long-Acting Insulin) Market Value, By Application, 2021-2030 (US$ Million)

Table 31 Middle East & Africa Basal Insulin (Long-Acting Insulin) Market Value, By Distribution Channels, 2021-2030 (US$ Million)

Table 32 Novo Nordisk AS: Overview

Table 33 Novo Nordisk AS: Product Portfolio

Table 34 Novo Nordisk AS: Key Developments

Table 35 Sanofi Aventis: Overview

Table 36 Sanofi Aventis: Product Portfolio

Table 37 Sanofi Aventis: Key Developments

Table 38 Biocon: Overview

Table 39 Biocon: Product Portfolio

Table 40 Biocon: Key Developments

Table 41 Julphar: Overview

Table 42 Julphar: Product Portfolio

Table 43 Julphar: Key Developments

Table 44 Pfizer: Overview

Table 45 Pfizer: Product Portfolio

Table 46 Pfizer: Key Developments

Table 47 Ganli Pharmaceutical Co., Ltd: Overview

Table 48 Ganli Pharmaceutical Co., Ltd: Product Portfolio

Table 49 Ganli Pharmaceutical Co., Ltd: Key Developments

Table 50 Mylan: Overview

Table 51 Mylan: Product Portfolio

Table 52 Mylan: Key Developments

Table 53 Eli Lilly: Overview

Table 54 Eli Lilly: Product Portfolio

Table 55 Eli Lilly: Key Developments

Table 56 Wockhardt: Overview

Table 57 Wockhardt: Product Portfolio

Table 58 Wockhardt: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Basal Insulin (Long-Acting Insulin) Market Value, 2021-2030 (US$ Million)

Figure 2 Global Basal Insulin (Long-Acting Insulin) Market Share, By Product Type, 2022 & 2030 (%)

Figure 3 Global Basal Insulin (Long-Acting Insulin) Market Share, By Application, 2022 & 2030 (%)

Figure 4 Global Basal Insulin (Long-Acting Insulin) Market Share, By Distribution Channels, 2022 & 2030 (%)

Figure 5 Global Basal Insulin (Long-Acting Insulin) Market Share, By Region, 2022 & 2030 (%)

Figure 6 Global Basal Insulin (Long-Acting Insulin) Market Y-o-Y Growth, By Product Type, 2022-2030 (%)

Figure 7 Lantus Basal Insulin (Long-Acting Insulin) Market Value, 2021-2030 (US$ Million)

Figure 8 Levemir Basal Insulin (Long-Acting Insulin) Market Value, 2021-2030 (US$ Million)

Figure 9 Toujeo Basal Insulin (Long-Acting Insulin) Market Value, 2021-2030 (US$ Million)

Figure 10 Tresiba Basal Insulin (Long-Acting Insulin) Market Value, 2021-2030 (US$ Million)

Figure 11 Basaglar Basal Insulin (Long-Acting Insulin) Market Value, 2021-2030 (US$ Million)

Figure 12 Insulin Glargine Biosimilars Basal Insulin (Long-Acting Insulin) Market Value, 2021-2030 (US$ Million)

Figure 13 Global Basal Insulin (Long-Acting Insulin) Market Y-o-Y Growth, By Application, 2022-2030 (%)

Figure 14 Type 1 Diabetes Application in Global Basal Insulin (Long-Acting Insulin) Market Value, 2021-2030 (US$ Million)

Figure 15 Type 2 Diabetes Application in Global Basal Insulin (Long-Acting Insulin) Market Value, 2021-2030 (US$ Million)

Figure 16 Global Basal Insulin (Long-Acting Insulin) Market Y-o-Y Growth, By Distribution Channels, 2022-2030 (%)

Figure 17 Hospital Pharmacies Distribution Channels in Global Basal Insulin (Long-Acting Insulin) Market Value, 2021-2030 (US$ Million)

Figure 18 Retail Pharmacies Distribution Channels in Global Basal Insulin (Long-Acting Insulin) Market Value, 2021-2030 (US$ Million)

Figure 19 Online Pharmacies Distribution Channels in Global Basal Insulin (Long-Acting Insulin) Market Value, 2021-2030 (US$ Million)

Figure 20 Global Basal Insulin (Long-Acting Insulin) Market Y-o-Y Growth, By Region, 2022-2030 (%)

Figure 21 North America Basal Insulin (Long-Acting Insulin) Market Value, 2021-2030 (US$ Million)

Figure 22 Asia-Pacific Basal Insulin (Long-Acting Insulin) Market Value, 2021-2030 (US$ Million)

Figure 23 Europe Basal Insulin (Long-Acting Insulin) Market Value, 2021-2030 (US$ Million)

Figure 24 South America Basal Insulin (Long-Acting Insulin) Market Value, 2021-2030 (US$ Million)

Figure 25 Middle East and Africa Basal Insulin (Long-Acting Insulin) Market Value, 2021-2030 (US$ Million)

Figure 26 North America Basal Insulin (Long-Acting Insulin) Market Value, 2021-2030 (US$ Million)

Figure 27 North America Basal Insulin (Long-Acting Insulin) Market Share, By Product Type, 2022 & 2030 (%)

Figure 28 North America Basal Insulin (Long-Acting Insulin) Market Share, By Application, 2022 & 2030 (%)

Figure 29 North America Basal Insulin (Long-Acting Insulin) Market Share, By Distribution Channels, 2022 & 2030 (%)

Figure 30 North America Basal Insulin (Long-Acting Insulin) Market Share, By Country, 2022 & 2030 (%)

Figure 31 South America Basal Insulin (Long-Acting Insulin) Market Value, 2021-2030 (US$ Million)

Figure 32 South America Basal Insulin (Long-Acting Insulin) Market Share, By Product Type, 2022 & 2030 (%)

Figure 33 South America Basal Insulin (Long-Acting Insulin) Market Share, By Application, 2022 & 2030 (%)

Figure 34 South America Basal Insulin (Long-Acting Insulin) Market Share, By Distribution Channels, 2022 & 2030 (%)

Figure 35 South America Basal Insulin (Long-Acting Insulin) Market Share, By Country, 2022 & 2030 (%)

Figure 36 Europe Basal Insulin (Long-Acting Insulin) Market Value, 2021-2030 (US$ Million)

Figure 37 Europe Basal Insulin (Long-Acting Insulin) Market Share, By Product Type, 2022 & 2030 (%)

Figure 38 Europe Basal Insulin (Long-Acting Insulin) Market Share, By Application, 2022 & 2030 (%)

Figure 39 Europe Basal Insulin (Long-Acting Insulin) Market Share, By Distribution Channels, 2022 & 2030 (%)

Figure 40 Europe Basal Insulin (Long-Acting Insulin) Market Share, By Country, 2022 & 2030 (%)

Figure 41 Asia-Pacific Basal Insulin (Long-Acting Insulin) Market Value, 2021-2030 (US$ Million)

Figure 42 Asia-Pacific Basal Insulin (Long-Acting Insulin) Market Share, By Product Type, 2022 & 2030 (%)

Figure 43 Asia-Pacific Basal Insulin (Long-Acting Insulin) Market Share, By Application, 2022 & 2030 (%)

Figure 44 Asia-Pacific Basal Insulin (Long-Acting Insulin) Market Share, By Distribution Channels, 2022 & 2030 (%)

Figure 45 Asia-Pacific Basal Insulin (Long-Acting Insulin) Market Share, By Country, 2022 & 2030 (%)

Figure 46 Middle East & Africa Basal Insulin (Long-Acting Insulin) Market Value, 2021-2030 (US$ Million)

Figure 47 Middle East & Africa Basal Insulin (Long-Acting Insulin) Market Share, By Product Type, 2022 & 2030 (%)

Figure 48 Middle East & Africa Basal Insulin (Long-Acting Insulin) Market Share, By Application, 2022 & 2030 (%)

Figure 49 Middle East & Africa Basal Insulin (Long-Acting Insulin) Market Share, By Distribution Channels, 2022 & 2030 (%)

Figure 50 Novo Nordisk AS: Financials

Figure 51 Sanofi Aventis: Financials

Figure 52 Biocon: Financials

Figure 53 Julphar: Financials

Figure 54 Pfizer: Financials

Figure 55 Ganli Pharmaceutical Co., Ltd: Financials

Figure 56 Mylan: Financials

Figure 57 Eli Lilly: Financials

Figure 57 Wockhardt: Financials

글로벌 기저 인슐린(지속형 인슐린) 시장 – 2023-2030

Global Basal Insulin (Long-Acting Insulin) Market - 2023-2030